30 closest matches · ranked by relevance
Cancer · Brain Tumors
Primary: Area Under the Receiver Operating Curve (ROC AUC) Values for PET Imaging Techniques — 0.98; 0.91; 0.89; 0.82 Probability
Urothelial Bladder Cancer · Triple-negative Breast Cancer · Pancreatic Ductal Adenocarcinoma
Primary: Percentage of Patients With Confirmed Overall Response During Tremelimumab Monotherapy Phase — 18.8; 8.3; 0.0 Percentage of Patients
Solid Tumor
Primary: Number of Participants With Adverse Events Due to MSOT Imaging — 0 Participants
Non-Small Cell Lung Cancer · Metastatic Non-small Cell Lung Cancer · Squamous Cell Carcinoma
Primary: Rate of Dose Limiting Toxicity (DLT) — 17 % participants w severe toxicity
Glioma
Primary: Response, Defined as Stable Disease or Objective (Partial or Complete) Response. — 0; 0; 0; 0 Participants
Brain Cancer · Gliomas
Primary: Determine & Comp Biodistribution, Clearance, & Dosimetry of [18F]FACBC & [18F]FLT Tissue/Organs w/i the Field of View of the Dynamic PET Imag Studies prior-to & During…
Glioblastoma · Gliosarcoma · Anaplastic Astrocytoma
Primary: Progression-free Survival at 6 Months — 23 Percentage of participants
Rheumatoid Arthritis · Ankylosing Spondylitis · Psoriatic Arthritis
Primary: Measurement of Effector T Helper Type 17 Cells in Peripheral Blood — 466.4; 432; 450; 759.8 spSFC/10^6 — p=0.003
Neuroendocrine Tumors · Carcinoid Tumors · Neuroblastoma
Primary: Number of Participants With a Change in Treatment Management Based on Findings of the Gallium Ga 68-edotreotide PET/CT Scan — 54; 6; 54 Participants
Solid Malignancy · Solid Tumor
Primary: Response Rate (RR) — 1 Participants
Brain Metastases
Primary: Percentage of the Gross Tumor Volume With a BTB Opening of Ktrans > 0.005 Min-1 — 78.6; 85.6; 6.4; 74.4 percentage of gross tumor volume
Carcinoid Tumor · Metastatic Carcinoid Tumor · Neuroendocrine Neoplasm
Primary: PFS — 11 months
Carcinoid Tumor · Carcinoid Tumor of GI System · Neuroendocrine Tumors
Primary: Objective Response Rate (ORR) — 0 percentage of participants
Tuberous Sclerosis · Subependymal Giant Cell Astrocytoma
Primary: Number With Observed Adverse Side Effects — 26; 25; 15; 14 participants
Breast Cancer · LCIS · DCIS
Primary: Quality of Life as Measured by the Breast Q — 61.9; 57.6; 74.2; 64.2 score on a scale
Primary Inoperable Thymoma · Local Recurrent Thymoma
Primary: Percent Change in Tumor Volume From Baseline to EOS — -37.38 percentage of tumor volume
Gastrinoma · Glucagonoma · Insulinoma
Primary: Confirmed Response Rate — 10; 14 percentage of participants
High-grade Glioma · Lung Cancer · Head & Neck Cancer
Primary: Correlation of the Magnitude of [18F]Fluciclatide Uptake and Retention With Quantitative Measurement of the Levels of αvβ3 (Beta-3 Integrin) Integrin Expression in…
Central Nervous System Neoplasm · Glioma · Metastatic Malignant Neoplasm in the Central Nervous System
Primary: Contrast-to-noise Ratio (CNR) — 60.6; 58.4 contrast-to-noise ratio
Neoplasm
Primary: Proportion of Patients With a Reportable Genetic Variant — 0.61 proportion of participants
Squamous Cell Cancer of the Oral Cavity
Primary: Percent of Ki-67 Positive Cells — .4023; .5872; .3732; .5035 percentage of stained tumor cell nuclei
Central Nervous System Lymphoma · Malignant Glioma · Metastatic Malignant Neoplasm in the Brain
Primary: Utility of Femumoxytol and Gadolinium Based Contrast Agents for Improved Imaging Biomarkers of Malignant Brain Tumors in a Single Session by Comparing Dynamic Contrast…
Vestibular Schwannoma · NF2 · Neurofibromatosis 2
Primary: Median Steady-state Lapatinib Plasma Concentrations at the Time of Surgical Resection — 3149 ng/mL
Neuroendocrine Tumors · Neuroendocrine Neoplasm of Lung
Primary: Clinical Benefit Rate (CBR) — 0; 0; 0; 1 Participants
Suspected Central Nervous System Tumors
Primary: Sensitivity (SBR) — 5.49 ratio
Solid Tumor
Primary: The Primary Objective of the Dose Finding Component is to Determine the Maximum Tolerated Dose (MTD) of HCW9218 — 1.2 mg/kg
Biopsy Proven Non Small Cell Lung Cancer · Head and Neck Cancer · Gastrointestinal Cancer
Primary: Tumor Volume — 93.55 cm^3
Cancer
Primary: Response and Progression Will be Evaluated in This Study Using the New International Criteria Proposed by the Response Evaluation Criteria in Solid Tumors (RECIST)…
Neurofibromatosis 1
Primary: Improvement of Symptoms and Pain — 9 Participants
Adult Rhabdomyosarcoma · Adult Synovial Sarcoma · Childhood Hepatoblastoma
Primary: Disease Response — 10; 10; 19; 10 patient